Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan:Treatment response,side effects and future prospective

被引:1
作者
Yasir Waheed [1 ]
机构
[1] Atta ur Rahman School of Applied Biosciences,National University of Sciences & Technology(NUST),Islamabad 44000,Pakistan
关键词
Hepatitis C virus; Interferon therapy; Genotype; 3;
D O I
暂无
中图分类号
R512.63 [];
学科分类号
100401 ;
摘要
More than 10 million people are suffering from hepatitis C virus(HCV) in Pakistan,The available treatment option is a combination of interferon and ribavirin.Treatment response is linked with several factors and also induces a number of side effects.We searched in Pubmed.Pak Medi Net and Coogle Scholar for the articles presenting the effect of interferon plus ribavirin therapy on HCV patients from Pakistan,their side effects and future prospects.The major prevalent HCV genotype in Pakistan is 3.Conventional interferon alpha plus ribavirin showed sustained virological response of 54%-64%while pegylaled interferon alpha plus ribavirin showed sustained virological response of 58%-75%.IL-28 B CC genotype is linked with better sustained virological response.Studies on patients with HCV genotype 3 infections showed no correlation between treatment response and interferon sensitivity determining region mutations.Interferon therapy is linked with a number of side effects like thyroid dysfuncton.hactnatological disorders,weight loss,gastrointestinal tract side effects and neuropsychiatric side effects.Unusual side effects of clubbing of fingers and seizures were also observed in a couple of patients.Interferon alpha plus ribavirin therapy showed better response rate in HCV genotype 3 patients from Pakistan with number of side effects.A couple of interferon free therapies are light of hope for the patients living with HCV.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 11 条
[1]   Hepatitis C virus in Pakistan:A systematic review of prevalence,genotypes and risk factors [J].
Yasir Waheed ;
Talha Shafi ;
Sher Zaman Safi ;
Ishtiaq Qadri .
World Journal of Gastroenterology, 2009, 15 (45) :5647-5653
[2]   Genetic diversity of the hepatitis C virus: Impact and issues inthe antiviral therapy [J].
H Le Guillou-Guillemette ;
S Vallet ;
C Gaudy-Graffin ;
C Payan ;
A Pivert ;
A Goudeau ;
F Lunel-Fabiani .
World Journal of Gastroenterology, 2007, (17) :2416-2426
[3]  
RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs[J] . Yasir Waheed,Attya Bhatti,Muhammad Ashraf. Infection, Genetics and Evolution . 2013
[4]  
Association of Interferon-Alpha and Ribavirin-Induced Thyroid Dysfunction with Severity of Disease and Response to Treatment in Pakistani Asian Patients of Chronic Hepatitis C[J] . Amina Nadeem,Muhammad Aslam,Alessandro Antonelli. <journal-title>Hepatitis Research and Treatment . 2012
[5]   Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients [J].
Aziz, Hafsa ;
Raza, Abida ;
Waheed, Yasir ;
Gill, Uzma ;
Gill, Muzaffar Lateef .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 (08) :E597-E602
[6]  
Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis[J] . Hafsa Aziz,Abida Raza,Shahnaz Murtaza,Yasir Waheed,Ali Khalid,Javaid Irfan,Zahoor Samra,Muhammad Amin Athar. International Journal of Infectious Diseases . 2012
[7]   Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan [J].
Aziz, Hafsa ;
Gil, Muzaffar Latif ;
Waheed, Yasir ;
Adeeb, Uzama ;
Raza, Abida ;
Bilal, Iram ;
Athar, Muhammad Amin .
INFECTION GENETICS AND EVOLUTION, 2011, 11 (03) :640-645
[8]  
Seizures During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C: Observations From the WIN-R Trial[J] . Furqaan Ahmed,Ira M. Jacobson,Jorge L. Herrera,Myron Brand,Ronald B. Wasserman,Alan M. Fixelle,Vinod K. Rustgi,Clive Albert,Robert Brown,Clifford Brass. Journal of Clinical Gastroenterology . 2011 (3)
[9]   Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus [J].
Thompson, Alexander J. ;
Muir, Andrew J. ;
Sulkowski, Mark S. ;
Ge, Dongliang ;
Fellay, Jacques ;
Shianna, Kevin V. ;
Urban, Thomas ;
Afdhal, Nezam H. ;
Jacobson, Ira M. ;
Esteban, Rafael ;
Poordad, Fred ;
Lawitz, Eric J. ;
McCone, Jonathan ;
Shiffman, Mitchell L. ;
Galler, Greg W. ;
Lee, William M. ;
Reindollar, Robert ;
King, John W. ;
Kwo, Paul Y. ;
Ghalib, Reem H. ;
Freilich, Bradley ;
Nyberg, Lisa M. ;
Zeuzem, Stefan ;
Poynard, Thierry ;
Vock, David M. ;
Pieper, Karen S. ;
Patel, Keyur ;
Tillmann, Hans L. ;
Noviello, Stephanie ;
Koury, Kenneth ;
Pedicone, Lisa D. ;
Brass, Clifford A. ;
Albrecht, Janice K. ;
Goldstein, David B. ;
McHutchison, John G. .
GASTROENTEROLOGY, 2010, 139 (01) :120-+
[10]   Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy [J].
Young, KC ;
Lindsay, KL ;
Lee, KJ ;
Liu, WC ;
He, JW ;
Milstein, SL ;
Lai, MMC .
HEPATOLOGY, 2003, 38 (04) :869-878